HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazuki Hirahara Selected Research

3- (2- (2- phenyl- 4- (4- pyridin- 4- ylbenzyl)morpholin- 2- yl)ethyl)quinazoline- 2,4(1H,3H)- dione

12/2009Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazuki Hirahara Research Topics

Disease

2Inflammation (Inflammations)
07/2012 - 01/2003
2Atopic Dermatitis (Atopic Eczema)
12/2009 - 01/2003
2Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
03/2006 - 01/2006
2Hypersensitivity (Allergy)
03/2005 - 01/2003
1Neoplasms (Cancer)
01/2021
1Seasonal Allergic Rhinitis (Hay Fever)
08/2011
1Sneezing
03/2005
1Allergic Rhinitis
03/2005
1Asthma (Bronchial Asthma)
01/2003

Drug/Important Bio-Agent (IBA)

3AntigensIBA
07/2012 - 01/2003
2Immunoglobulin E (IgE)IBA
07/2012 - 01/2003
2AllergensIBA
08/2011 - 03/2005
2T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
08/2011 - 03/2005
1Glycoproteins (Glycoprotein)IBA
01/2021
1Melanocortin Receptors (Melanocortin Receptor)IBA
07/2012
1Melanocyte-Stimulating Hormones (MSH)IBA
07/2012
1pullulanIBA
08/2011
1Protein Subunit VaccinesIBA
08/2011
1OligodeoxyribonucleotidesIBA
08/2011
1VaccinesIBA
08/2011
1DNA VaccinesIBA
08/2011
1Complex MixturesIBA
08/2011
13- (2- (2- phenyl- 4- (4- pyridin- 4- ylbenzyl)morpholin- 2- yl)ethyl)quinazoline- 2,4(1H,3H)- dioneIBA
12/2009
1Interleukin-7 (Interleukin 7)IBA
03/2006
1Interleukin-18 (Interleukin 18)IBA
01/2006
1Histamine (Histamine Dihydrochloride)FDA Link
03/2005
1P2-246-259IBA
03/2005

Therapy/Procedure

2Immunotherapy
01/2021 - 08/2011
1Oral Administration
03/2005